BioCentury
ARTICLE | Clinical News

Cavatak: Interim Phase II data

January 7, 2013 8:00 AM UTC

Interim data from 13 evaluable patients with stage IIIc/IV malignant melanoma in the first stage of a 2-stage, open-label, U.S. Phase II trial showed that 10 intratumoral injections of Cavatak produce...